SEPN Stock Analysis: Buy, Sell, or Hold?
SEPN - Septerna, Inc. Common Stock
$40.00
-0.79 (-1.94%)
▼
5d:
-10.11%
30d:
+19.51%
90d:
+43.27%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When SEPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SEPN is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SEPN is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SEPN is currently trading at $40.00, which is considered fair relative to its 30-day fair value range of $33.05 to $42.99.
Technical Outlook: Technically, SEPN is in a strong uptrend. Immediate support is located at $38.05, while resistance sits at $51.10.
Market Sentiment: SEPN scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.11 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SEPN is in a strong uptrend. Immediate support is located at $38.05, while resistance sits at $51.10.
Market Sentiment: SEPN scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.11 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$33.05 -
$42.99
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.9% below Wall St target ($53.11)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$33.05 -
$42.99
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$38.05
Resistance Level
$51.10
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.02
Wall Street Target
$53.11
(+20.9%)
Revenue Growth (YoY)
22375.6%
Profit Margin
-24.5%
Share & Embed Analysis
Last updated: August 23, 2026 5:19 PM ET
Data refreshes hourly during market hours. Next update: 6:19 PM
Data refreshes hourly during market hours. Next update: 6:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Elizabeth Bhatt
SELL
4000 shares
2026-04-15
Samira Shaikhly
SELL
70453 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
